Fibroblast growth factor 23 and the future of phosphorus management

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 6, 2009, Pages 463-468

  Wolf, Myles ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

1,25 dihydroxyvitamin O; Cardiovascular disease; Fibroblast growth factor 23; Mortality; Phosphorus

Indexed keywords

BIOLOGICAL MARKER; CALCIFEDIOL; CALCITRIOL; DOXECALCIFEROL; ERGOCALCIFEROL DERIVATIVE; FIBROBLAST GROWTH FACTOR 23; PARICALCITOL; PHOSPHATE; PHOSPHORUS; PHOSPHORUS DERIVATIVE; UNCLASSIFIED DRUG; UREMIC TOXIN; VITAMIN D; VITAMIN D DERIVATIVE; CHELATING AGENT; FIBROBLAST GROWTH FACTOR;

BONE MINERALIZATION; CELL FUNCTION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; MINERAL METABOLISM; MORTALITY; NONHUMAN; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PHOSPHATURIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW; TREATMENT RESPONSE; UREMIA; VALIDATION PROCESS; VITAMIN D DEFICIENCY; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION; ANIMAL; BLOOD; CHRONIC DISEASE; KIDNEY DISEASE; PATIENT SELECTION; PREDICTION AND FORECASTING; RENAL REPLACEMENT THERAPY; REPRODUCIBILITY; RISK ASSESSMENT; UPREGULATION;

ANIMALS; BIOLOGICAL MARKERS; CALCITRIOL; CHELATING AGENTS; CHRONIC DISEASE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY DISEASES; PATIENT SELECTION; PHOSPHORUS; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; UP-REGULATION;

EID: 73349135032     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328331a8c8     Document Type: Review

References (58)

1. Anonymous. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium. Nat Genet 2000; 26:345348.
2. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008; 118:3820-3828.
3. Prie D, Urena Torres P, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int 2009; 75:882-889.
4. Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1 alpha, 25-dihydroxyvitamin D3 production. J Biol Chem 2003; 278:2206-2211. (Pubitemid 36801287)
5. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19:429-435. (Pubitemid 38787398)
6. Bai XY, Miao D, Goltzman D, Karaplis AC. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 2003; 278:9843-9849. (Pubitemid 36800487)
7. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 In oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-1663. (Pubitemid 36459471)
8. Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003; 112:683-692. (Pubitemid 38057709)
9. Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemia rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002; 143:31793182. (Pubitemid 34809892)
10. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemia rickets with reduced expression of sodium phosphate cotransportertype Na. Biochem Biophys Res Commun 2004; 314:409414. (Pubitemid 38084732)
11. Sitara D, Razzaque MS, Hesse M, et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesls, and reverses hypophosphatemia in Phex-deficlent mice. Matrix Biol 2004; 23:421-432. (Pubitemid 39576657)
12. Ferrari SL, Bonjour JP, Rizzoli R. FGF-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90:1519-1524. (Pubitemid 40464013)
13. Saito H, Maeda A, Ohtomo S, et al. Circulating FGF-23 Is regulated by 1 alpha, 25-dihydroxyvltamin D3 and phosphorus in vivo. J Biol Chem 2005; 280: 2543-2549. (Pubitemid 40189356)
14. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91:3144-3149. (Pubitemid 44271770)
15. Burnett SM, Gunawardene SC, Bringhurst FR, et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21:1187-1196.
16. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444:770-774. (Pubitemid 44949607)
17. Farrow EG, Davis SI, Summers LJ, White KE. Initial FGF23-medlated signaling occurs In the distal convoluted tubule. J Am Soc Nephrol 2009; 20:955960. Although the effects of FGF23 on phosphorus handling and vitamin D occur in the proximal tubule, this study demonstrated that the initial FGF23 signaling occurs at the site of membrane-bound klotho expression in the distal tubule.
18. Ito N, Fukumoto S, Takeuchi Y, et al. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels In humans. J Bone Miner Metab 2007; 25:419-422. (Pubitemid 350043699)
19. Burnett-Bowie SM, Mendoza N, Leder BZ. Effects of gonadal steroid with-drawal on serum phosphate and FGF-23 levels in men. Bone 2007; 40:913918. (Pubitemid 46394616)
20. Gupta A, Winer K, Econs MJ, et al. FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 2004; 89:4489-4492.
21. Wesseling-Perry K, Pereira RC, Wang H, et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009; 94:511-517.
22. Sitara D, Kim S, Razzaque MS, et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 2008; 4:e1000154.
23. Urena Torres P, Friedlander G, de Vernejoul MC, et al. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney lnt 2008; 73:102-107. (Pubitemid 350273643)
24. Wang H, Yoshiko Y, Yamamoto R, et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 2008; 23:939-948. (Pubitemid 351768812)
25. Schouten BJ, Hunt PJ, Livesey JH, et al. FGF23 elevation and hypophosphataemia following intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009; 94:2332-2337. This study demonstrated that intravenous iron could stimulate massive secretion of FGF23 causing an acute, reversible hypophosphatemia osteomalacia syndrome.
26. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 2003; 285: E1-E9. (Pubitemid 36736355)
27. Kumar R. Phosphate sensing. Curr Opin Nephrol Hypertens 2009; 18:281-284.
28. Mulroney SE, Woda CB, Halaihel N, et al. Central control of renal sodium-phosphate (NaPi-2) transporters. Am J Physiol Renal Physiol 2004; 286:F647-652. (Pubitemid 38365082)
29. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16:2205-2215. (Pubitemid 41716454)
30. Larsson T, Nlsbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney lnt 2003; 64:2272-2279. (Pubitemid 37449564)
31. ShigematsuT, Kazama JJ, Yamashita T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44:250-256. (Pubitemid 38962552)
32. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:22082218.
33. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney lnt 2006; 70:771-780.] (Pubitemid 44215354)
34. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72:1004-1013. (Pubitemid 47530570)
35. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584-592. This prospective study of 400 incident hemodialysis patients was the first to demonstrate an association between increased FGF23 levels at baseline and subsequent risk of mortality. The results for FGF23 were far stronger than comparable analyses of serum phosphate and mortality and thereby positioned FGF23 as a novel and sensitive biomarker of toxicity due to disordered phosphorus metabolism in CKD.
36. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16:1115-1125. (Pubitemid 41710323)
37. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168:397-403. (Pubitemid 351350586)
38. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 11 7:503-511.
39. Melamed ML, Michos ED, Post W, Astor B. 25-Hydroxyvitamln D levels and the risk of mortality In the general population. Arch Intern Med 2008; 168:16291637.
40. Giovannuccl E, Liu Y, Hollis BW, Rimm EB. 25-Hydroxyvitamln D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008; 168:1174-1180. (Pubitemid 351831400)
41. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009; 75:88-95.
42. Nishi H, Nii-Kono T, Nakanishi S, et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2005; 101:c94-c99. (Pubitemid 41208897)
43. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349:446456. (Pubitemid 36910023)
44. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-281.
45. Jean G, Terrat JC, Vanel T, et al. High levels of serum fibroblast growth factors (FGF)-23 are associated with increased mortality In long haemodialysls patients. Nephrol Dial Transplant 2009; 24:2792-2796. In a population of prevalent hemodialysis patients and in which almost half of patients were treated with active vitamin D, increased FGF23 was associated with mortality on dialysis. These results support the idea that FGF23 is a predictor of mortality even when there Is potential confounding by vitamin D therapy.
46. Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005; 67:1171-1178. (Pubitemid 41623344)
47. Roos M, Lutz J, Salmhofer H, et al. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography In patients with normal kidney function. Clin Endocrinol (Oxf) 2008; 68:660-665.
48. Mirza MA, Hansen T, Johansson L, et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 2009 [Epub ahead of print].
49. Inaba M, Okuno S, Imanishi Y, et al. Role of fibroblast growth factor-23 In peripheral vascular calcification in nondiabetic and diabetic hemodialysis patients. Osteoporos Int 2006; 17:1506-1513. (Pubitemid 44387485)
50. Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552. In a cross-sectional study of predialysis and non-CKD patients who had normal mean serum phosphate levels, Increased FGF23 was independently associated with increased left ventricular mass index and greater prevalence of left ventricular hypertrophy. The association between increased FGF23 and coronary artery calcification was less conclusive.
51. Hsu HJ, Wu MS. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy In hemodialysis patients. Am J Med Sei 2009; 337: 116-122.
52. Mirza MA, Larsson A, Melhus H, et al. Serum intact FGF23 associated with left ventricular mass, hypertrophy and geometry In an elderly population. Atherosclerosis 2009 [Epub ahead of print]. In a large community-based cross-sectional study, higher FGF23 levels were independently associated with increased left ventricular mass index and greater prevalence of left ventricular hypertrophy.
53. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205:385-390. In a large community-based cross-sectional study, higher FGF23 levels were associated with impaired vascular reactivity and increased arterial stiffness. This is the largest study linking FGF23 to dynamic measures of vascular function.
54. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18:2600-2608.
55. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390:45-51. (Pubitemid 27494749)
56. Yu X, lbrahimi OA, Goetz R, et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005; 146:4647-4656.
57. Kuro-o M. Klotho In chronic kidney disease: what's new? Nephrol Dial Transplant 2009; 24:1705-1708.
58. Isakova T, Gutiérrez OM, Wolf M. A blueprint for randomized trials targeting phosphorus metabolism In chronic kidney disease. Kidney lnt 2009 [Epub ahead of print].